Top 10 NASDAQ Stocks with Highest Upside: YRCW, PPHM, CYTR, ALIM, ATHX, SNSS, NABI, VRML, TRMD, EPCT (Nov 15, 2011)

TAPINDER KATOCH INVESTMENTS
YRC Worldwide Inc. (NASDAQ:YRCW) has the 1st highest upside potential in this segment of the market. Its upside is 1568.7%. Its consensus target price is $0.69 based on the average of all estimates. Peregrine Pharmaceuticals (NASDAQ:PPHM) has the 2nd highest upside potential in this segment of the market. Its upside is 612.5%. Its consensus target price is $7.13 based on the average of all estimates. CytRx Corporation (NASDAQ:CYTR) has the 3rd highest upside potential in this segment of the market. Its upside is 558.1%. Its consensus target price is $2.57 based on the average of all estimates. Alimera Sciences Inc (NASDAQ:ALIM) has the 4th highest upside potential in this segment of the market. Its upside is 532.9%. Its consensus target price is $10.00 based on the average of all estimates. Athersys, Inc. (NASDAQ:ATHX) has the 5th highest upside potential in this segment of the market. Its upside is 443.2%. Its consensus target price is $7.23 based on the average of all estimates.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has the 6th highest upside potential in this segment of the market. Its upside is 429.4%. Its consensus target price is $6.75 based on the average of all estimates. Nabi Biopharmaceuticals (NASDAQ:NABI) has the 7th highest upside potential in this segment of the market. Its upside is 426.3%. Its consensus target price is $10.00 based on the average of all estimates. Vermillion, Inc. (NASDAQ:VRML) has the 8th highest upside potential in this segment of the market. Its upside is 387.8%. Its consensus target price is $6.00 based on the average of all estimates. Torm A/S (ADR) (NASDAQ:TRMD) has the 9th highest upside potential in this segment of the market. Its upside is 369.4%. Its consensus target price is $4.51 based on the average of all estimates. EpiCept Corporation (NASDAQ:EPCT) has the 10th highest upside potential in this segment of the market. Its upside is 363.0%. Its consensus target price is $1.67 based on the average of all estimates.